A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis ...

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis ...

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis Oct. 25, 2024 8:05 AM ET Johnson & Johnson (JNJ) ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Guselkumab can effectively and safely treat patients with psoriasis for up to 2 years, according to a study.“Guselkumab is the first human IgG1 lambda monoclonal antibody that inhibits ...

Dermatology > Psoriasis Psoriasis Control Maintained Long Term With Extended Dosing Interval of Guselkumab — More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color.